All In Biotech

Drug Trial Radar · NCT06581432

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

588

Planned (sponsor's estimate)

Start

Oct 11, 2024

Primary completion

Nov 30, 2028

Study completion Dec 29, 2028

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into groups based on the type of advanced cancer they have, the type of HER2 alterations they have, and the dose of zongertinib they receive. Depending on the group they are in, participants take 1 of 2 different doses of zongertinib each day. Participants can continue the treatment as long as they benefit from it and can tolerate it. Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.

Conditions

  • Solid Tumours

Interventions

  • ZongertinibDrug

    Zongertinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with objective response (OR)Time frame: Up to 51 months

Locations

93 sites in 16 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology, LLC

    Anchorage, Alaska · Recruiting

  • University of Arizona Comprehensive Cancer Center

    Tucson, Arizona · Completed

  • Precision NextGen Oncology

    Beverly Hills, California · Recruiting

  • Scripps Cancer Center Torrey Pines

    La Jolla, California · Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • BRCR Global - Tamarac

    Tamarac, Florida · Recruiting

  • Illinois Cancer Specialists

    Arlington Heights, Illinois · Recruiting

  • Community MD Anderson Cancer Center - East Medical Oncology

    Indianapolis, Indiana · Recruiting

  • Maryland Oncology Hematology, Columbia

    Columbia, Maryland · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Completed

  • Presbyterian Healthcare Services

    Albuquerque, New Mexico · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • Alliance Cancer Specialists, PC, Wynnewood

    Wynnewood, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute at Mary Crowley

    Dallas, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Texas Oncology - Plano West

    Plano, Texas · Recruiting

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia · Recruiting

  • Macquarie University

    Macquarie Park, New South Wales, Australia · Recruiting

  • GenesisCare North Shore

    St Leonards, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Cancer Research South Australia

    Adelaide, South Australia, Australia · Recruiting

  • St John of God Subiaco Hospital

    Subiaco, Western Australia, Australia · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium · Recruiting

  • Cross Cancer Institute (University of Alberta)

    Edmonton, Alberta, Canada · Recruiting

  • BC Cancer Agency - Vancouver

    Vancouver, British Columbia, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Centre Hospitalier de l'Universite de Montreal (CHUM)

    Montreal, Quebec, Canada · Recruiting

  • McGill University Health Centre (MUHC)

    Montreal, Quebec, Canada · Completed

  • Peking University First Hospital

    Beijing, China · Recruiting

  • Hunan Province Tumor Hospital

    Changsha, China · Not yet recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

    Hangzhou, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, China · Not yet recruiting

  • Shanghai East Hospital

    Shanghai, China · Recruiting

  • Shanghai GoBroad Cancer Hospital

    Shanghai, China · Recruiting

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.